These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 17225316)

  • 41. Enfuvirtide (Fuzeon).
    Proj Inf Perspect; 2003 Oct; (36):4-5. PubMed ID: 14696566
    [TBL] [Abstract][Full Text] [Related]  

  • 42. A randomized pilot study comparing combination therapy plus enfuvirtide versus a treatment interruption followed by combination therapy plus enfuvirtide.
    Beatty G; Hunt P; Smith A; Hoh R; Huang W; Martin J; Deeks SG
    Antivir Ther; 2006; 11(3):315-9. PubMed ID: 16759047
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Analysis of a switch from enfuvirtide to raltegravir in patients with undetectable viral load: efficacy and quality of life at 24 weeks.
    Sayana S; Prosser P; Ricaurte JC; Sanchez S; Hamwi G; Hershey-Weber J; Chien C; Easley A; Nguyen T; Wilson L; Khanlou H
    J Int Assoc Physicians AIDS Care (Chic); 2009; 8(2):85-6. PubMed ID: 19369697
    [No Abstract]   [Full Text] [Related]  

  • 44. Formal approval for Fuzeon.
    AIDS Patient Care STDS; 2004 Dec; 18(12):736. PubMed ID: 15659885
    [No Abstract]   [Full Text] [Related]  

  • 45. Needle-free Fuzeon in works.
    AIDS Patient Care STDS; 2005 Sep; 19(9):614. PubMed ID: 16164388
    [No Abstract]   [Full Text] [Related]  

  • 46. [Enfuvirtida (Fuzeon). Laboratory: Roche & Trimeris].
    Moreno Alvarez PJ
    Farm Hosp; 2003; 27(4):271-2. PubMed ID: 12966457
    [No Abstract]   [Full Text] [Related]  

  • 47. T-20 and adefovir for salvage therapy -- expect no miracles.
    Gilden D
    GMHC Treat Issues; 1998 Apr; 12(4):6-7. PubMed ID: 11365400
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Enfuvirtide, an HIV-1 fusion inhibitor.
    Carr A
    N Engl J Med; 2003 Oct; 349(18):1770-1; author reply 1770-1. PubMed ID: 14585947
    [No Abstract]   [Full Text] [Related]  

  • 49. [Fusion inhibitors. One year therapy with T-20--initial evaluation].
    Goebel FD
    MMW Fortschr Med; 2004 Apr; 146 Spec No 1():42-3. PubMed ID: 15373046
    [No Abstract]   [Full Text] [Related]  

  • 50. Change in HIV-1 DNA tropism despite virological success in patients receiving an enfuvirtide-based regimen.
    Charpentier C; Joly V; Ghosn J; Yeni P; Raffi F; Descamps D; Morand-Joubert L
    J Antimicrob Chemother; 2014 Sep; 69(9):2588-90. PubMed ID: 24816213
    [No Abstract]   [Full Text] [Related]  

  • 51. Misleading efficacy claims for Fuzeon.
    AIDS Patient Care STDS; 2005 Sep; 19(9):614. PubMed ID: 16247841
    [No Abstract]   [Full Text] [Related]  

  • 52. [Enfuvirtide desensitisation: due to a failed case].
    López-de-Torre Querejazu A; Ibarra Barrueta O; Santos Ibañez A; Mayo Suárez J
    Farm Hosp; 2012; 36(2):112-3. PubMed ID: 22024011
    [No Abstract]   [Full Text] [Related]  

  • 53. David Reddy--taking HIV therapy to new frontiers. Interview by Pam Das.
    Reddy D
    Lancet Infect Dis; 2003 Feb; 3(2):110-3. PubMed ID: 12560198
    [No Abstract]   [Full Text] [Related]  

  • 54. US FDA approves new class of HIV therapeutics.
    Robertson D
    Nat Biotechnol; 2003 May; 21(5):470-1. PubMed ID: 12721558
    [No Abstract]   [Full Text] [Related]  

  • 55. Fuzeon combination highly effective.
    AIDS Patient Care STDS; 2006 Dec; 20(12):888. PubMed ID: 17219619
    [No Abstract]   [Full Text] [Related]  

  • 56. [Strategies for combating resistances in HIV therapy--an exemplifying case].
    Stoehr A
    MMW Fortschr Med; 2004 Apr; 146 Spec No 1():70-1. PubMed ID: 15373056
    [No Abstract]   [Full Text] [Related]  

  • 57. [FDA approved the first of a new class of antiretrovirals for adults and children with advanced HIV infection].
    Rev Panam Salud Publica; 2003 Jul; 14(1):57-8. PubMed ID: 12952609
    [No Abstract]   [Full Text] [Related]  

  • 58. Darunavir offers potent new combo when used with enfuvirtide in ritonavir-boosted regimen.
    Edmunds-Ogbuokiri T
    HIV Clin; 2007; 19(1):1-3. PubMed ID: 17405221
    [No Abstract]   [Full Text] [Related]  

  • 59. Clinical trials for enfuvirtide (Fuzeon, T-20).
    Crabb C
    AIDS; 2003 Nov; 17(17):N13-4. PubMed ID: 15065580
    [No Abstract]   [Full Text] [Related]  

  • 60. Sustained HIV RNA suppression after switching from enfuvirtide to etravirine in the early access programme.
    Loutfy M; Ribera E; Florence E; De Wit S; Castagna A; Ryan R; Hill A; Vanaken H; van Delft Y; Marks S
    J Antimicrob Chemother; 2009 Dec; 64(6):1341-4. PubMed ID: 19828488
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.